Osteoporosis in men;Actualización Clínica/Un Problema Clínico Frecuente: Osteoporosis en el varón

Revista Clinica Espanola

Volumn 210, Issue 7, 2010, Pages 342-349

  Moro Alvarez M J ^a   Biazquez Cabrera J A ^b  

^a HOSPITAL CENTRAL DE LA CRUZ ROJA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

Author keywords

Bisphosphonates; Fractures; Male hypogonadism; Man; Osteopenia; Osteoporosis; Prevention; Teriparatide; Testosterone; Treatment

Indexed keywords

ADULT; ALGORITHM; CASE REPORT; HUMAN; MALE; OSTEOPOROSIS; PRACTICE GUIDELINE; REVIEW;

ADULT; ALGORITHMS; HUMANS; MALE; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC;

EID: 77956674601     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/j.rce.2009.11.023     Document Type: Note

References (61)

1. Center JR, Nguyen HD, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: An observational study. Lancet. 1999;35:878-82.
2. Kiebzak GM, Beinart GA, Perser K, Ambrose CG, Siff SJ, Heggeness MH. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med. 2002;162:2217-22.
3. Díaz López JB, Naves Díaz M, Gómez Alonso C, Fernández Martín JL, Rodríguez Rebollar A, Cannata Andía JB. Prevalencia de fractura vertebral en población asturiana mayor de 50 años de acuerdo con diferentes criterios radiológicos. Med Clin (Barc). 2000;115:326-31.
4. Schuit SC, Van der Klift M, Weel AE, De Laet CE, Burger H, Seeman E, et al. Fracture incidence and association with bone mineral density in elderly men and women: The Rotterdam Study. Bone. 2004;34:195-202.
5. Francis RM, Peacock M, Aaron JE. Osteoporosis in hypogonadal men: Role of decreased 1,25- dihydroxyvitamin D, calcium malabsorption and low bone formation. Bone. 1986;7:261-8.
6. Spencer H, Rubio N, Rubio E, Indreika M, Seitam A. Chronic alcoholism: Frecuently overlooked cause of osteoporosis in men. Am J Med. 1986;80:393-7.
7. Rapado A, Yague M, Diaz Curiel M. Osteoporosis en el varón. Med Clin (Barc). 1990;95:389-93.
8. Peris P, Guanabens N, Monegal A, Suris X, Álvarez L, Martínez de Osaba MJ, et al. Aetiology and presenting symptoms in male osteoporosis. Br J Rheumatol. 1995;34:936-41.
9. Barrett-Connor E, Mueller JE, Von Mühlen DG, Laughlin GA, Schneider DL, Sartoris DJ. Low levels of estradiol are associated with vertebral fractures in older men, but not women: The Rancho Bernardo Study. J Clin Endocrinol Metab. 2000;85:219-23.
10. Vanderschueren D, Bouillon R. Androgens and bone. Calcif Tissue Int. 1995;56:341-6.
11. Riggs BL, Melton LJ, Robb RA, Camp JJ, Atkinson EJ, McDaniel L, et al. A population-based assessment of rates of bone loss at multiple skeletal sites: Evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res. 2008;23:205-14.
12. Israeli RS, Ryan CW, Jung LL. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J Urol. 2008;179:414-23.
13. Body JJ, Bergmann P, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club. Osteoporos Int. 2007;18:1439-50.
14. Diamond TH, Bucci J, Kersley JH, Aslan P, Lynch WB, Bryant C. Osteoporosis and spinal fractures in men with prostate cancer: Risk factors and effects of androgen deprivation therapy. J Urol. 2004;172:529-32.
15. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized controlled trial. J Clin Endocrinol Metab. 2004;89:3841-6.
16. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: A randomized trial. Ann Intern Med. 2007;146:416-24.
17. Ishizaka K, Machida T, Kobayashi S, Kanbe N, Kitahara S, Yoshida K. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. Int J Urol. 2007;14:1071-5.
18. Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, et al. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors forbone loss on androgen deprivation therapy. J Urol. 2009;182:2257-64.
19. Israeli RS, Rosenberg SJ, Saltzstein DR, Gottesman JE, Goldstein HR, Hull GW, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer. 2007;5:271-7.
20. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745-755.
21. Greenspan SL. Approach to the prostate cancer patient with bone disease. J Clin Endocrinol Metab. 2008;93:2-7.
22. Santolaria F, González-Reimers E, Pérez-Manzano JL, Milena A, Gómez-Rodríguez MA, González-Díaz A, et al. Osteopenia assessed by body composition analysis is related to malnutrition in alcoholic patients. Alcohol. 2000;22:147-57.
23. Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev. 2008;29:441-64.
24. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20:1185-94.
25. Cummings SR, Cawthon PM, Ensrud KE, Cauley JA, Fink HA, Orwoll ES, Osteoporotic Fractures in Men (MrOS) Research Groups. Study of Osteoporotic Fractures Research Groups. BMD and risk of hip and nonvertebral fractures in older men: A prospective study and comparison with older women. J Bone Miner Res. 2006;21:1550-6.
26. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ, Khaltaev N, et al. A reference standard for the description of osteoporosis. Bone. 2008;42:467-75.
27. Meier C, Nguyen TV, Center JR, Seibel MJ, Eisman JA. Bone resorption and osteoporotic fractures in elderly men: The Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res. 2005;20:579-87.
28. Meier C, Nguyen TV, Handelsmman DJ, Schindler C, Kushnir MM, Rockwood AL, et al. Endogenous sex hormones and incident fracture risk in older men: The Dubbo Osteoporosis Epidemiology Study. Arch Intern Med. 2008;168:47-54.
29. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, et al. Assessment of fracture risk. Osteoporos Int. 2005;16:581-9.
30. Kanis JA, Black D, Cooper C, Dargent P, Dawson-Hughes B, De Laet C, et al. A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int. 2002;13:527-36.
31. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18:1033-46.
32. Schousboe JT, Taylor BC, Fink HA, Kane RL, Cummings SR, Orwoll ES, et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA. 2007;298:629-37.
33. Jackson JA, Kleerekoper M. Osteoporosis in men: Diagnosis, pathophysiology and prevention. Medicine. 1990;69:139-52.
34. Tang BM, Eslik GD, Nowson C, Simth C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: A meta analysis. Lancet. 2007;370:657-66.
35. NIH releases consensus statement on optimal calcium intake. Am Fam Physician. 1994;50(6):1385-7.
36. Ringe JD, Dorst A, Faber H, Ibach K. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int. 2004;24:110-3.
37. Gonnelli S, Cepollaro C, Montagnani A, Bruni D, Caffarelli C, Breschi M, et al. Alendronate treatment in men with primary osteoporosis: A three-year longitudinal study. Calcif Tissue Int. 2003;73:133-9.
38. Shimon I, Eshed V, Doolman R, Sela BA, Karasik A, Vered I. Alendronate for osteoporosis in men with androgen-repleted hypogonadism. Osteoporos Int. 2005;16:1591-6.
39. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343:604-10.
40. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone MinerRes. 2000;15:1006-13.
41. Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: Results of a 1-year study. Rheumatol Int. 2006;26:427-31.
42. Ringe JD, Farahmand P, Faber H, Dorst A. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: Results of a 2-year study. Rheumatol Int. 2009;29:311-5.
43. Sato Y, Iwamoto J, Kanoko T, Satoh K. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Ann Intern Med. 2005;165:1743-8. (Pubitemid 41138962)
44. Iwamoto J, Takeda T, Sato Y. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis-usefulness of alendronate and risedronate. Expert Opin Pharmacother. 2007;8:2743-56.
45. LeBlanc AD, Driscol TB, Shackelford LC, Evans HJ, Rianon NJ, Smith SM. Alendronate as an effective countermeasure to disuse induced bone loss. J Musculoskelet Neuronal Interact. 2002;2:335-43.
46. Milgrom C, Finestone A, Novack V, Pereg D, Goldich Y, Kreiss Y, et al. The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits. Bone. 2004;35:418-24.
47. Lamy O, Sandini L, Pache I, Fatio S, Burnand J, Burckhardt P. Intravenous ibandronate in men with osteoporosis: An open pilot study over 2 years. J Endocrinol Invest. 2003;26:728-32.
48. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-809.
49. Jarrett SJ, Conaghan PG, Sloa VS, Papanastasiou P, Ortmann CE, O'Connor PJ, et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum. 2006;54:1410-4.
50. Rosen CJ, Bilezikian JP. Anabolic therapy for osteoporosis. J Clin Endocrinol Metab. 2001;86:957-64.
51. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Pérez A, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18:9-17.
52. Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: Treatment and discontinuation of therapy. Osteoporos Int. 2005;16:510-6.
53. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers. J Clin Endocrinol Metab. 2000;85:3069-76.
54. Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med. 2008;358:1474-82.
55. Miller P, Lindsay R, Watts N, Meeves S, Lang T, Delmas P, Bilezikian J, et al. Patients previously treated with risedronate demonstrate greater responsiveness to teriparatide than those previously treated with alendronate: The OPTAMISE study. J Bone Miner Res. 2007;22:S26.
56. Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1-34)]. Osteoporos Int. 2004;15:992-7.
57. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004;89:503-10.
58. Finkelstein JS, Klibanski A, Neer RM, Doppelt SH, Rosenthal DI, Segre GV, et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 1989;69:776-83.
59. Sosa M, Segarra MC, Hernandez D, González A, Limiñana JM, Betancor P. Epidemiology of proximal femoral fracture in Gran Canaria (Canary Island). Age Ageing. 1993;22:285-8.
60. Anderson FH, Francis RM, Faulkner K. Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone. 1996;18:171-7.
61. NNOF's New Clinician's Guide to Prevention and Treatment of Osteoporosis. 2008 [consultado 4/7/2009]. Disponible en: www.nof.org/professionals/ Clinicians-Guide.htm.